Public Meeting on Idiopathic Pulmonary Fibrosis Patient-Focused Drug Development

  • Dates: 26 Sep, 2014
  • Location: Silver Spring, Maryland, United States of America
On September 26, 2014, FDA is conducting a public meeting on Patient-Focused Drug Development for idiopathic pulmonary fibrosis (IPF). FDA is interested in obtaining patient input on the impact of IPF on daily life and patients’ views on currently available therapies to treat the condition.

The Pulmonary Fibrosis Foundation (PFF) has submitted survey data from more than 1,100 patients and families suffering from pulmonary fibrosis (PF) to the FDA for the meeting.

Learn More

Time
1:00 p.m.-5:00 p.m. EST

Location

FDA White Oak Campus
10903 New Hampshire Ave.
Building 31, Room 1503B and C (Great Room)
Silver Spring, MD 20993
(Information about arrival to FDA's White Oak campus)

Registration
To register for this meeting, visit: Public Meeting on Idiopathic Pulmonary Fibrosis Patient-Focused Drug Development

Registration has been extended and will close on September 17, 2014

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >